Market research
4OD.F Odonate Therapeutics, Inc
F EUR Not available
Latest close
As of 04 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 48M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- 0.0%
- Beta
- 0.18
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 48M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- 0.0%
- Beta
- 0.18
About
About Odonate Therapeutics, Inc
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Research context
Odonate Therapeutics, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 4OD.F discussion.
5 years, 7 months ago
Odonate Therapeutics, Inc is currently in a long term downtrend where the price is trading 70.5% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Odonate Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 15.9% to $-32M since the same quarter in the previous year.
Finally, its free cash flow fell by 28.5% to $-32M since the same quarter in the previous year.
Based on the above factors, Odonate Therapeutics, Inc gets an overall score of 1/5.